The growing use of GLP-1 therapies is prompting employers to rethink how they support workforce health. As demand increases, multinationals are facing important questions around access, affordability and long-term health outcomes.
Dr Leena Johns, Chief Health and Wellness Officer at MAXIS GBN, will be hosting a webinar for International Federation of Health Plan (IFHP) members on 9 November, 5pm ET. She’ll be sharing key insights from the MAXIS 2026 whitepaper, drawing on medical claims data covering more than 7.9 million insured lives worldwide.
Going beyond the headlines, the whitepaper explores emerging claims trends, why GLP-1s should be viewed as more than weight-loss drugs, and the considerations employers should take into account when developing their approach to these therapies.
For more information, contact [email protected].